Fortress Biotech Inc
Research Fortress Biotech Inc (FBIO) on Bullrun: market cap USD 71.29M, P/E 0.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 71.29M
- P/E0.8
- Financial periodQ2 2026
- RevenueUSD 18.72M
- Net income-USD 468.00K
- Free cash flow-USD 59.36M
- Gross margin67.2%
Valuation Snapshot
latest market cap is USD 71.29M; P/E is 0.8.
Peer valuation comparison
Latest P/E is 0.81x versus a Healthcare sector median of 24.61x (96.7% below).
Latest P/E is 0.81x versus a United States median of 23.85x (96.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 63.26M | USD 37.00M | -USD 65.78M | 66.9% | -0.07 | USD 79.38M | USD 54.49M | USD 49.87M |
| FY2024 | USD 57.68M | USD 21.00M | -USD 80.19M | 63.8% | -2.69 | USD 57.26M | USD 57.96M | USD 22.74M |
| FY2023 | USD 84.51M | USD 31.00M | -USD 128.29M | 72.9% | -8.47 | USD 80.93M | USD 60.86M | USD 22.54M |
| FY2022 | USD 75.74M | -USD 86.58M | -USD 182.12M | 59.4% | -15.97 | USD 178.27M | USD 91.73M | USD 41.72M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 71.29M | 0.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 114.79M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 56.65M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 45.37M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 71.69M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 253.59M | n/a | n/a | n/a |
About Fortress Biotech Inc
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fortress Biotech Inc's market cap?
Fortress Biotech Inc's market capitalization is USD 71.29M.
What is Fortress Biotech Inc's P/E ratio?
Fortress Biotech Inc's price-to-earnings (P/E) ratio is 0.8.
What does Fortress Biotech Inc do?
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally.